Medifocus to Attend the 23rd Video Urology World Congress in Hong Kong on November 9-11
Published: Oct 22, 2012
COLUMBIA, MD and TORONTO--(Marketwire - October 22, 2012) -
While Medifocus' FDA approved Prolieve® system is currently available to patients suffering from benign prostatic hyperplasia (BPH) in the U.S. only, Medifocus believes the emerging middle class and the growing aging population in Asia will adopt the best medical technology available and create significant commercial potential for the Company's Prolieve® system, in addition to other of the Company's product lines in the future. Attending the conference is one of the first initiatives Medifocus is actively pursuing. This will allow the Company to establish a presence in the Asia-Pacific region for the development, clinical testing, regulatory approval, promotion and marketing of its Prolieve® system and cancer treatment technology portfolio.
Prolieve® is a patent-protected device that utilizes intra-cavitary catheters to deliver a combination of microwave heating and balloon dilatation of the prostatic urethra, which leads to the relief of BPH symptoms. Treatment with Prolieve® is a minimally invasive non-surgical in-office procedure which offers patients clinically documented immediate reduction of BPH symptom scores. Prolieve® is the only microwave device to be randomized to drug therapy during its pivotal trial. The BPH drug market is an $8 billion market and growing. BPH patients can be treated using Prolieve® in urologic offices throughout the United States. In addition, the Prolieve® treatment is also made available to physicians using the Company's nationwide mobile service provider, Rocky Mountain Mobile Services.
Medifocus owns a patented microwave focusing technology platform (the Adaptive Phased Array ("APA") technology), which can precisely target and control microwave energy to cause heating in cancerous tumors anywhere in the body reliably and repeatedly. The ability to target tumors with a precision controlled dose of heat can be used to destroy tumors at higher temperatures, to treat tumors in combination with chemotherapy and/or radiation at moderate temperatures for increased effectiveness and reduced toxicity and to trigger the targeted release of therapeutic drugs and genes at tumor sites at lower temperatures. While the core technology has been licensed from the Massachusetts Institute of Technology, Medifocus has further refined the precision of the microwave focusing and control ability and developed a commercial system dedicated exclusively for the treatment of Breast Cancer.
With the buy-back (acquisition) of Prolieve, Medifocus now owns a revenue-generating commercial BPH heat treatment product, generating cash flow to support the development and commercialization of other catheter based or APA based external focused heat systems for targeted thermotherapy of deep-seated tumors anywhere in the body. Please visit www.medifocusinc.com for more information.
Forward-Looking Statements and Information
This news release contains forward-looking statements, which may not be based on historical facts. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by applicable securities laws, the Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.
For further information about the Company:
Chief Operating Officer
Telephone (410) 290-5734